Form 6-K NOVO NORDISK A S For: May 06
- Wall Street falls after open on rate hike woes
- S&P 500 Could Rally Almost 10% From Here, Bank of America's Suttmeier Suggests
- Face-ripping Rallies and Market Slumps is What Wells Fargo is Telling Clients to Prepare for This Summer
- JPMorgan Reiterates Amazon, Booking, and Uber as Top Internet Stocks to Own
- Pinterest (PINS) CEO Silbermann Is Stepping Down, Shares Gain 8%
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 6, 2022
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
DK- 2880, Bagsvaerd
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|Form 20-F [X]||Form 40-F [ ]|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|Yes [ ]||No [X]|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo Nordisk – major shareholder announcement
Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.
The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights.
For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
|Ambre Brown Morley||+45 3079 9289||[email protected]|
|Natalia Salomao Abrahao (US)||+1 848 304 1027||[email protected]|
|Daniel Muusmann Bohsen||+45 3075 2175||[email protected]|
|Ann Søndermølle Rendbæk||+45 3075 2253||[email protected]|
|David Heiberg Landsted||+45 3077 6915||[email protected]|
|Jacob Martin Wiborg Rode||+45 3075 5956||[email protected]|
|Mark Joseph Root (US)||+1 848 213 3219||[email protected]|
Annex: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 3 May 2022
|Name||% of voting rights if it equals or is higher than the notifiable threshold||% of voting rights through financial instruments if it equals or is higher than the notifiable threshold||Total of both if it equals or is higher than the notifiable threshold|
|BlackRock Japan Co., Ltd.||Below 5%|
|BlackRock Investment Management, LLC||Below 5%|
|BlackRock Investment Management (UK) Limited||Below 5%|
|BlackRock Investment Management (Australia) Limited||Below 5%|
|BlackRock International Limited||Below 5%|
|BlackRock Institutional Trust Company, National Association||Below 5%|
|BlackRock Fund Advisors||Below 5%|
|BlackRock Financial Management, Inc.||Below 5%|
|BlackRock Asset Management North Asia Limited||Below 5%|
|BlackRock Asset Management Deutschland AG||Below 5%|
|BlackRock Asset Management Canada Limited||Below 5%|
|BlackRock Advisors, LLC||Below 5%|
|BlackRock Advisors (UK) Limited||Below 5%|
|BlackRock (Singapore) Limited||Below 5%|
|BlackRock Asset Management Ireland Limited||Below 5%|
|Aperio Holdings, LLC||Below 5%|
Novo Nordisk A/S
+45 4444 8888
24 25 67 90
|Company announcement No 44 / 2022|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|Date: May 6, 2022||
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Announces AGM Results
- UBS Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell
- June 29 is World Scleroderma Day
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!